{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:14:36Z","timestamp":1778649276772,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus (VZV). Cancer patients, due to immune suppression, are at an increased risk of HZ. However, the exact relationship between cancer and the occurrence of HZ remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study collected data from cancer patients diagnosed between 01\/01\/2020, and 30\/09\/2024. Descriptive statistics were used to summarize the clinical characteristics of HZ patients. Propensity score matching (PSM) was applied to match HZ and non-HZ groups in a 1:3 ratio, controlling for potential confounding factors. Logistic regression analysis was performed to investigate the impact of cancer type, treatment modalities, and other factors on the occurrence of HZ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 99 HZ patients, the onset of HZ was closely associated with the timing of anticancer treatment, with 89.89% of patients developing HZ within 12 months after the first anticancer therapy. After PSM matching, cancer type was identified as a significant independent risk factor for HZ. Patients with hematologic cancers, such as multiple myeloma, had a significantly higher risk of developing HZ compared to those with solid tumors (OR\u00a0=\u00a02.41, 95% CI 1.11-5.24, P\u00a0=\u00a00.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hematologic malignancy patients are at a significantly higher risk of developing HZ compared to those with solid tumors. The use of immune checkpoint inhibitors (ICIs) did not significantly increase the risk of HZ. These findings suggest that patients with hematologic cancers should be closely monitored for HZ and undergo preventive measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1804448","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:50:40Z","timestamp":1778647840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canhua","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GuangZhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyi","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2023149","DOI":"10.5826\/dpc.1303a149","article-title":"Dermoscopic features of herpes zoster: Case series and review of the literature","volume":"13","author":"Bazzacco","year":"2023","journal-title":"Dermatol Pract Conceptual"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1038\/s41467-024-49112-4","article-title":"Identification and characterization of varicella zoster virus circular RNA in lytic infection","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.70126","article-title":"Clinical progress note: Varicella zoster","volume":"20","author":"Zhang","year":"2025","journal-title":"J Hosp Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00170","article-title":"CT-guided stellate ganglion pulsed radiofrequency stimulation for facial and upper limb postherpetic neuralgia","volume":"13","author":"Ding","year":"2019","journal-title":"Front Neurosci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694344","article-title":"Mechanism of the immunomodulatory effect of the combination of live bifidobacterium, lactobacillus, enterococcus, and bacillus on immunocompromised rats","volume":"12","author":"Lv","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1752563","article-title":"Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection","volume":"9","author":"Pan","year":"2020","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/infdis\/jiy625","article-title":"Risk of herpes zoster prior to and following cancer diagnosis and treatment: A population-based prospective cohort study","volume":"220","author":"Qian","year":"2019","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: Population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2313-2","article-title":"Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years","volume":"106","author":"Park","year":"2017","journal-title":"Int J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0467-z","article-title":"Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma","volume":"33","author":"Song","year":"2019","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1345-x","article-title":"The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma","volume":"39","author":"Crawford","year":"2020","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1565480","article-title":"Drug-induced herpes zoster: A pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024","volume":"16","author":"Xia","year":"2025","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2024.01.027","article-title":"Risk factors and the effect of antiviral prophylaxis for herpes zoster in multiple myeloma patients","volume":"32","author":"Wang","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/jh1085","article-title":"Adverse hematological and non-hematological events in patients with relapsed\/refractory multiple myeloma that are responsive to daratumumab, pomalidomide and dexamethasone","volume":"12","author":"Alkharabsheh","year":"2023","journal-title":"J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.843032","article-title":"Efficacy of intermittent, oral famciclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/ejh.13810","article-title":"Herpes zoster prophylaxis with low-dose acyclovir in patients with Malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation","volume":"109","author":"Abbasov","year":"2022","journal-title":"Eur J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: Have we found the key to unleash the antitumor immune response","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/cco-23-153","article-title":"A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment","volume":"13","author":"Hirano","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.033","article-title":"Varicella zoster virus encephalitis mimicking nivolumab-induced autoimmune neuropathy in a patient with lung cancer","volume":"14","author":"Watanabe","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13377","article-title":"Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report","volume":"11","author":"Gozzi","year":"2020","journal-title":"Thorac Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0318","article-title":"Herpes zoster in patients with lung cancer treated with PD-1\/PD-L1 antibodies","volume":"14","author":"Nagai","year":"2022","journal-title":"Immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s579681","article-title":"MPNFS framework for managing herpes zoster and refractory pain in an immunotherapy-treated lung cancer patient: A case report","volume":"18","author":"Qiao","year":"2026","journal-title":"Cancer Manage Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2764","article-title":"Herpes zoster in lung cancer patients treated with PD-1\/PD-L1 inhibitors","volume":"11","author":"Taoka","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2288282","article-title":"The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy","volume":"19","author":"Lasagna","year":"2023","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100548","article-title":"Vaccination for herpes zoster in patients with solid tumors: A position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)","volume":"7","author":"Pedrazzoli","year":"2022","journal-title":"ESMO Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.11.005","article-title":"Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis","volume":"74","author":"Schmidt","year":"2017","journal-title":"J Infection"},{"key":"B29","doi-asserted-by":"publisher","first-page":"21541","DOI":"10.1038\/s41598-024-72893-z","article-title":"Associations of head and neck cancers with herpes zoster in the preceding five years","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41467-024-45852-5","article-title":"Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus","volume":"15","author":"Wan","year":"2024","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1186\/s12885-019-6349-y","article-title":"Increased risk of lymphoid Malignancy in patients with herpes zoster: A longitudinal follow-up study using a national cohort","volume":"19","author":"Choi","year":"2019","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198208123070701","article-title":"Risk of cancer after herpes zoster: A population-based study","volume":"307","author":"Ragozzino","year":"1982","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1804448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:50:44Z","timestamp":1778647844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1804448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1804448"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1804448","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1804448"}}